Acutaas Chemicals Limited
Pharmaceuticals
Annual Returns


Cumulative Returns and Drawdowns


Ownership

Margined

AI Summary
asof: 2026-09-16
ACUTAAS Chemicals — Recent Developments Summary
1. Headwinds and Challenges
- Sequential moderation in Q1 FY27: Revenue from
operations declined 23.8% QoQ to ₹3,297 Mn (from ₹4,328 Mn in Q4 FY26),
and PAT fell 44.2% QoQ to ₹750 Mn (from ₹1,343 Mn). EBITDA margin
contracted to 34.3% in Q1 FY27 from 42.4% in Q4 FY26, and gross margin
eased to 57.9% from 62.0%.
- Muted commodity chemicals: Within Specialty
Chemicals, strong growth in BFC was offset by muted performance in
commodity chemicals.
- Lower other income: PAT margin expansion in Q1 FY27
was driven by strong EBITDA margins but was offset by lower other income
(₹18 Mn in Q1 FY27 versus ₹159 Mn in Q1 FY26).
- Subsidiary losses: Subsidiary ACEPL reported a
profit after tax of (37.3) million and a net worth of (58.3) million for
FY 2025-26.
- GST inspection: An inspection/search under Section
67(2) of the Central Goods and Services Tax Act, 2017 was conducted by
the Additional Commissioner of CGST & Central Excise, Anti-evasion
Department, Surat, at the company’s Registered Office and manufacturing
unit at Sachin, Surat. The search concluded on June 23, 2026; the
company provided all requested documents and clarifications, and no
official document has been issued by the CGST department. The company
states there is no material impact on financials, operations, or other
activities.
- Forward-looking statement risk: Forward-looking
statements are subject to known and unknown risks and uncertainties that
may or may not occur, and actual results may differ substantially.
2. Tailwinds and Growth Prospects
- Strong Q1 FY27 growth: Revenue from operations grew
59.1% YoY to ₹3,297 Mn; EBITDA rose 122.1% YoY to ₹1,131 Mn; PAT rose
70.4% YoY to ₹750 Mn. Gross profit grew 73.0% YoY.
- CDMO and core intermediates: CDMO continued strong
growth momentum, and the core Advanced intermediate business delivered
robust growth.
- Margin drivers: EBITDA margins were supported by
better product mix and operational efficiencies.
- Semiconductor materials scale-up: The step-down
subsidiary Indichem Inc. inaugurated its semiconductor materials
manufacturing plant at Gongju, South Korea, on August 28, 2026,
completed within 11 months of its September 29, 2025 groundbreaking.
AAML (wholly owned subsidiary of Acutaas) and J & Materials Co. hold
a 75:25 stake in Indichem, with AAML having invested KRW 30 billion
(approx. ₹200 crore). The aim is to build a resilient, geographically
diversified supply chain for global chip and display makers through a
synergistic two-country model of Indian synthesis and Korean
refining.
- Electrolytes and battery chemicals roadmap: A
strategic roadmap envisages substantial scale-up in the electrolytes and
battery chemicals segment, expansion at the Jhagadia Unit-3 facility
with an investment aggregating to ₹1,950 million, and business
development and marketing via subsidiary ACEPL, providing multi-year
visibility on scale-up and execution across domestic and global
markets.
- Process patent: The Patent Office, Government of
India, granted a Process Patent for “A PROCESS FOR PREPARING
2,4-DIMETHYLTHIOPHENOL” on September 10, 2026, for a 20-year term from
the filing date of September 21, 2017. The process was indigenously
developed at the company’s R&D Centre, bringing total patents
granted to 11.
- Certifications: The company was certified as a
Great Place to Work and received Responsible Care certification from the
Indian Chemical Council.
- Investor engagement: Officials will physically
attend the Nuvama 21st India Investor Conference in Singapore on August
12, 2026, and the Equirus India Growth Summit in Mumbai on August 13,
2026.
3. Key Risks
- Forward-looking uncertainty: Known and unknown
risks and uncertainties could cause actual results to differ
substantially from expectations.
- Regulatory/inspection exposure: The GST
anti-evasion inspection at the Sachin registered office and
manufacturing unit, though concluded with no official document issued
and no stated material impact.
- Subsidiary financial weakness: ACEPL’s negative net
worth and loss for FY 2025-26.
- Commodity chemicals softness: Muted performance in
commodity chemicals offsetting BFC strength.
- Sequential volatility: Sharp QoQ declines in
revenue, EBITDA, and PAT indicate quarter-to-quarter variability.
- Dependence on other income: Lower other income
weighed on PAT margins despite strong EBITDA.
Broker Narrative
The broker narrative evolved from an initial 2024 Buy call citing no
tailwinds and warning of overcapacity, poor profitability, and LFP
technology access outside China, to a 2026 Buy call centered on CDMO
momentum, battery chemicals commercialization, and upgraded FY27 growth
and EBITDA margin guidance. Legacy headwinds persisted as Specialty
Chemicals revenue fell 20% YoY from lower-value phase-outs and commodity
chemicals remained weak even while Advanced Intermediates grew 53%. The
LFP technology risk receded once commercial revenue for VC and FEC
began, and management pulled CDMO revenue targets forward to FY27
alongside an ahead-of-schedule South Korea plant launch.
Fears that came true
- Early poor profitability fears materialized in the latest report’s
20% YoY Specialty Chemicals revenue decline and weaker commodity
chemical performance, occurring alongside the flat -0.2% actual return
on the final Buy call.
- Early overcapacity fears were echoed in the continued weaker
commodity chemical business performance noted in the final report,
corroborating earlier concerns about industry-wide capacity
pressure.
Broker Timeline
7 broker calls · 2024-11-01 to 2026-10-27
CNBC-TV18: ratings, targets and commentary
No recorded CNBC-TV18 statements for this ticker.
Management comments
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.
🐞